Melanoma screening: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) |
||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{YD}}; {{SSK}} | {{CMG}} {{AE}} {{YD}}; {{SSK}} | ||
==Overview== | ==Overview== | ||
The 1992-1994 free [[American Academy of Dermatology|American Academy of Dermatology's]] National [[Skin]] [[Cancer (disease)|Cancer]] Early [[Detection theory|Detection]] and [[Screening (medicine)|Screening]] Program provided broad [[skin]] [[Cancer (disease)|cancer]] [[Education|educational]] [[Information science|information]] to general [[Public health|public]] and enabled thousands of free [[Expert Patient Programme|expert]] [[skin]] [[Cancer (disease)|cancer]] [[Examination|examinations]]. The 2001-2005 [[American Academy of Dermatology]] National [[Melanoma]]/[[Skin]] [[Cancer (disease)|Cancer]] [[Screening (medicine)|Screening]] Program emphasized on the use of HARMM [[criteria]] to identify the higher-[[RiskMetrics|risk]] [[Subgroup analysis|subgroup]] of [[skin]] [[Cancer (disease)|cancer]] [[Screening (medicine)|screening]] [[Population (statistics)|population]] via [[Assessment and Plan|assessment]] of multiple [[risk factors]] for [[MM]] hence, both [[Reduced|reducing]] the [[Cost-effectiveness|cost]] & increasing the [[Yield (chemistry)|yields]] for suspected [[MM]] in [[Future interests (actuarial science)|future]] [[mass]] [[Screening (medicine)|screening]] [[Initiation (chemistry)|initiatives]]. [[Melanoma]] [[Genetics]] Program identifies the [[genetic]] [[causes]] of [[skin]] [[Cancer (disease)|cancer]], and provides [[genetic counseling]] to the [[Individual growth|individuals]] with [[strong]] [[family history]] of [[melanoma]]. [[Dermoscopy]] [[Usage analysis|usage]] [[Improving agent|improves]] the [[Ability grouping|ability]] of [[Primary care physician|primary care physicians]] to [[triage]] [[lesions]] [[Suggestion|suggestive]] of [[skin]] [[Cancer (disease)|cancer,]] thus saving from [[Unnecessary Fuss|unnecessary]] [[Expert Patient Programme|expert]] [[Consultation|consultations]]. [[Combination therapy|Combination]] of [[dermoscopy]] and short-term [[Sequential analysis|sequential]] [[Digital dictation|digital]] [[dermoscopy]] [[imaging]] (SDDI) in a [[Primary care provider|primary care setting]] doubles the [[Sensitivity (tests)|sensitivity]] for [[melanoma]] [[diagnosis]] and [[Lead|leads]] to >50% [[chance]] of [[reduction]] in [[excision]] or [[Reference|referral]] of [[benign]] [[pigmented lesions]]. | |||
==Screening== | ==Screening== | ||
According to different [[Study design|studies]] going on for so many [[Year|years]], following [[data]] is available regarding the different [[Method of Levels|methods]]/tools and their [[Effective method|effectiveness]] for [[skin]] [[Cancer (disease)|cancer]] [[Screening (medicine)|screening]]: | According to different [[Study design|studies]] going on for so many [[Year|years]], following [[data]] is available regarding the different [[Method of Levels|methods]]/tools and their [[Effective method|effectiveness]] for [[skin]] [[Cancer (disease)|cancer]] [[Screening (medicine)|screening]]: | ||
* From 1992 to 1994, free [[American Academy of Dermatology|American Academy of Dermatology's]] National [[Skin]] [[Cancer (disease)|Cancer]] Early [[Detection theory|Detection]] and [[Screening (medicine)|Screening]] Program was launched which provided broad [[skin]] [[Cancer (disease)|cancer]] [[Education|educational]][[Information science|information]] to general [[Public health|public]] and enabled almost 750,000 free [[Expert Patient Programme|expert]] [[skin]] [[Cancer (disease)|cancer]] [[Examination|examinations]] which mostly found out thin, [[Localized disease|localized]] stage 1 [[melanomas]] with high [[Project Halo|projected]] [[Five year survival rate|5-year survival rate]] | * From 1992 to 1994, free [[American Academy of Dermatology|American Academy of Dermatology's]] National [[Skin]] [[Cancer (disease)|Cancer]] Early [[Detection theory|Detection]] and [[Screening (medicine)|Screening]] Program was launched which provided broad [[skin]] [[Cancer (disease)|cancer]] [[Education|educational]] [[Information science|information]] to general [[Public health|public]] and enabled almost 750,000 free [[Expert Patient Programme|expert]] [[skin]] [[Cancer (disease)|cancer]] [[Examination|examinations]] which mostly found out thin, [[Localized disease|localized]] stage 1 [[melanomas]] with high [[Project Halo|projected]] [[Five year survival rate|5-year survival rate]] | ||
* From 2001 to 2005, [[American Academy of Dermatology]] National [[Melanoma]]/[[Skin]] [[Cancer (disease)|Cancer]] [[Screening (medicine)|Screening]] Program was launched which led to the conclusion that HARMM [[criteria]] can be [[Usage analysis|used]] to identify the higher-[[RiskMetrics|risk]] [[Subgroup analysis|subgroup]] of [[skin]] [[Cancer (disease)|cancer]] [[Screening (medicine)|screening]] [[Population (statistics)|population]] via [[Assessment and Plan|assessment]] of multiple [[risk factors]] for [[MM]] , which will not only [[Reduced|reduce]] the [[Cost-effectiveness|cost]] but will also increase the [[Yield (chemistry)|yields]] for suspected [[MM]] in [[Future interests (actuarial science)|future]] [[mass]] [[Screening (medicine)|screening]] [[Initiation (chemistry)|initiatives]] | * From 2001 to 2005, [[American Academy of Dermatology]] National [[Melanoma]]/[[Skin]] [[Cancer (disease)|Cancer]] [[Screening (medicine)|Screening]] Program was launched which led to the conclusion that HARMM [[criteria]] can be [[Usage analysis|used]] to identify the higher-[[RiskMetrics|risk]] [[Subgroup analysis|subgroup]] of [[skin]] [[Cancer (disease)|cancer]] [[Screening (medicine)|screening]] [[Population (statistics)|population]] via [[Assessment and Plan|assessment]] of multiple [[risk factors]] for [[MM]] , which will not only [[Reduced|reduce]] the [[Cost-effectiveness|cost]] but will also increase the [[Yield (chemistry)|yields]] for suspected [[MM]] in [[Future interests (actuarial science)|future]] [[mass]] [[Screening (medicine)|screening]] [[Initiation (chemistry)|initiatives]] | ||
* [[Melanoma]] [[Genetics]] Program identifies the [[genetic]] [[causes]] of [[skin]] [[Cancer (disease)|cancer]], and also provides [[genetic counseling]] to the [[Individual growth|individuals]] having a [[strong]] [[family history]] of [[melanoma]] | * [[Melanoma]] [[Genetics]] Program identifies the [[genetic]] [[causes]] of [[skin]] [[Cancer (disease)|cancer]], and also provides [[genetic counseling]] to the [[Individual growth|individuals]] having a [[strong]] [[family history]] of [[melanoma]] | ||
Revision as of 17:04, 16 July 2019
|
Melanoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Melanoma screening On the Web |
|
American Roentgen Ray Society Images of Melanoma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.
Overview
The 1992-1994 free American Academy of Dermatology's National Skin Cancer Early Detection and Screening Program provided broad skin cancer educational information to general public and enabled thousands of free expert skin cancer examinations. The 2001-2005 American Academy of Dermatology National Melanoma/Skin Cancer Screening Program emphasized on the use of HARMM criteria to identify the higher-risk subgroup of skin cancer screening population via assessment of multiple risk factors for MM hence, both reducing the cost & increasing the yields for suspected MM in future mass screening initiatives. Melanoma Genetics Program identifies the genetic causes of skin cancer, and provides genetic counseling to the individuals with strong family history of melanoma. Dermoscopy usage improves the ability of primary care physicians to triage lesions suggestive of skin cancer, thus saving from unnecessary expert consultations. Combination of dermoscopy and short-term sequential digital dermoscopy imaging (SDDI) in a primary care setting doubles the sensitivity for melanoma diagnosis and leads to >50% chance of reduction in excision or referral of benign pigmented lesions.
Screening
According to different studies going on for so many years, following data is available regarding the different methods/tools and their effectiveness for skin cancer screening:
- From 1992 to 1994, free American Academy of Dermatology's National Skin Cancer Early Detection and Screening Program was launched which provided broad skin cancer educational information to general public and enabled almost 750,000 free expert skin cancer examinations which mostly found out thin, localized stage 1 melanomas with high projected 5-year survival rate
- From 2001 to 2005, American Academy of Dermatology National Melanoma/Skin Cancer Screening Program was launched which led to the conclusion that HARMM criteria can be used to identify the higher-risk subgroup of skin cancer screening population via assessment of multiple risk factors for MM , which will not only reduce the cost but will also increase the yields for suspected MM in future mass screening initiatives
- Melanoma Genetics Program identifies the genetic causes of skin cancer, and also provides genetic counseling to the individuals having a strong family history of melanoma
- Dermoscopy usage improves the ability of primary care physicians to triage lesions which are suggestive of skin cancer and saves from unnecessary expert consultations
- Combination of dermoscopy and short-term sequential digital dermoscopy imaging (SDDI) in a primary care setting doubles the sensitivity for melanoma diagnosis and also leads to >50% chance of reduction in excision or referral of benign pigmented lesions